|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow: Chronic and Acute Heart Failure- Diverse Strategies for a Complex Disease
Datamonitor, Aug 2002
There is a need for new therapies for heart failure, as disease rates remain high. Current prevalence estimates for chronic heart failure range from 1-2% of the population, totaling over 13m patients in 7 major markets. The prognosis for heart failure patients is poor, with 5 year mortality rates between 61-68% in the US and EU. Greater understanding of heart failure has paved the way for novel therapeutic approaches. The diverse R&D pipeline includes 32 compounds in 14 novel drug classes.Evaluates patient potential categorized by age, disease, severity, and etiology, including a segmentation of chronic and acute heart failureReviews the role and limitations of existing drug and devicesProvides in-depth analysis of compounds in novel developmental drug classesAlthough the acute heart failure population represents a smaller market (1.2m hospitalizations in the US in 2002), it is a valid target for specialist niche companies due to the high level of unmet need.Diastolic heart failure, representing between 17-30% of the chronic heart failure population in the US and EU, has been widely neglected to the detriment of patients. Research in this area presents an opportunity for the pharmaceutical industry.The late-stage heart failure pipeline is weak in terms of quantity and quality. The combined revenue forecast for seven new compounds in 2010 is $2bn, provided they reach the market.Assesses the market appeal for R&D investment, providing an overview of developmental therapies, identifying promising candidates for in-licensing.Recognize key areas within the treatment of heart failure and heart failure sub-populations that remain inadequately served.Identify lucrative targets for developmental compounds, in terms of unmet need and patient potential, to successfully position developmental products.Access analyses of clinical and market factors along with forecasts for late-stage compounds in development for chronic and acute heart failure
Customers who bought this item also bought
Treatment Algorithms 2002: Heart failure - managing chronic and acute patients
Chronic and Acute Heart Failure - Diversity and Disappointment
Pipeline Insight: Heart failure Weak pipeline dominated by new indications and add-on diuretics
Stakeholder Opinions: Heart Failure - When Drugs Do Not Work
Stakeholder Insight: Heart Failure - Pumping Up Therapy Will Prevent Failure
Cardiovascular and Circulatory System - Congestive Heart Failure Drug Pipeline Report
Drugs of Tomorrow 2001: Stable Angina - An Unsatisfactory R&D Pipeline Facing Chronic Unmet Needs
Congestive Heart Failure Therapy Area Pipeline Report
US market size for angina, congestive heart failure and chronic obstructive pulmonary disease therapies by number of patients in 2000 forecast to 2005; also, number of CHF and COPD patients with prescription drug benefits, and users and dollar sales
Hypertension and Heart Failure - Evaluation and Management Clincial Guidelines
Hypertension Plus Heart Failure - Evaluation & Management Guidelines
Executive Brief � Home Health Monitoring for Heart Failure Patients
|
|
|
|
